Summary of Key Points
A doctor from a private hospital in Wenzhou was convicted of defrauding the medical insurance system by prescribing “preventive medication” for hemophiliac patients, for which insurance only covers treatment during episodes of bleeding. The doctor was sentenced to 2 years and 6 months in prison. This judgment breaks with the long-standing lax enforcement of medical insurance regulations in the industry, causing widespread anxiety among doctors nationwide who treat hemophiliacs. As a result, they have started to tighten their prescriptions (e.g., reducing dosages or requiring tests to confirm bleeding), making it more difficult for patients to obtain medication and delaying treatment. This incident exposes multiple issues, including conflicts between medical insurance policies and medical guidelines, legal uncertainties, and the infringement of patients' rights.
1. Doctors Suddenly Fear Prison Time: A Judgment Shatters an Industry’s Unspoken Agreement
For over a decade, medical insurance regulations have stipulated that adult hemophiliac patients could only use recombinant clotting factors when they were actually bleeding. However, doctors generally allowed more flexibility in practice, allowing severe patients to take the medication home for use as needed, without strictly adhering to the “bleeding-only” rule. It was only after the doctor in Wenzhou was convicted that everyone realized their long-standing practices might constitute a criminal offense.
Doctors’ reactions are now extreme: some refuse to treat hemophiliacs altogether, while others require urgent examinations (such as ultrasounds) to confirm bleeding before prescribing medication, even for cheaper, non-preventive clotting factors. The main fear is criminal responsibility (theft charges can carry up to life imprisonment) and potential fines for the hospital due to insurance regulations. A director from a top-tier hospital stated, “Proving the treatment was necessary has become more important than providing treatment itself; we need to protect ourselves first.”
2. Patients Face Incredible Difficulty in Obtaining Medication: By the Time Tests Are Completed, Damage Has Already Been Done
The judgment has significantly increased the barriers for patients to get their medication:
- Doses Reduced by Half: Medications that used to cover a month’s supply are now only available for a week or even a single dose.
- Forced to Switch to Cheaper Medications: Some hospitals no longer prescribe recombinant factors (which have no risk of infection) and require patients to use more expensive, blood-derived factors instead.
- Proof of Bleeding Required: Patients must undergo tests (ultrasounds, CT scans) to show active bleeding before receiving medication.
For hemophiliacs, bleeding can cause irreversible damage. Medical guidelines recommend immediate treatment within an hour of symptoms, but by the time the tests are completed, joint damage may have already occurred. Patient Lin Jian said, “The pain during a bleeding episode is excruciating, and then we have to go through all these unnecessary procedures. Isn’t that just torture?” Additionally, children can receive preventive treatment without needing to prove bleeding, but adults lose this benefit, rendering years of preventive care futile and potentially leading to disability.
3. Medical Insurance Regulations Lag Behind Medical Progress: Restrictions from a Decade Ago Have Become a Stumbling Block
Why did medical insurance initially restrict the use of recombinant factors for preventive treatment? The reason lies in historical costs: in 2009, when recombinant factors were first included in insurance, they were much more expensive than blood-derived factors. To control costs, the “bleeding-only” rule was implemented. However, with recent price reductions, the two types of factors are now nearly equivalent (both costing around 1.5 yuan per unit). This restriction is no longer justified.
More importantly, medical guidelines have long recommended preventive treatment, which can reduce bleeding and prevent disability. Although preventive treatment requires more frequent injections (once a week), the long-term cost is lower compared to the higher expenses associated with hospitalizations, joint replacements, and missed work due to bleeding. The disconnect between insurance regulations and best medical practices is at the heart of this controversy.
4. Legal Uncertainty: Is Prescribing According to Medical Guidelines Considered Fraud?
The doctor in Wenzhou’s main argument for appeal was that he did not receive any benefits or kickbacks and prescribed medication according to standard clinical practices, with no intent to defraud. Lawyers argue that fraud requires both “illegal intent” and “fabrication of facts.” In this case, the patient’s condition was real, and the treatment was necessary, though it fell outside the scope of insurance coverage.
It’s also worth noting that private hospital doctors are more likely to face legal consequences; public hospitals may protect their doctors through administrative penalties, but private hospitals have no such support, leaving doctors to bear the brunt of the issues. Lawyer Xia Ming warned, “Hemophiliacs are just the first case; similar issues could arise with other diseases in the future.”
5. Finding a Solution: Can Medical Insurance Regulations Align with Medical Needs?
Patient organizations have repeatedly called on the insurance authorities to repeal the restriction on the use of recombinant factors for preventive treatment in adults. Their arguments are compelling:
- The cost of recombinant factors has decreased, making insurance coverage more feasible.
- Preventive treatment can reduce disability and save money in the long run.
- The inconsistent policies for children and adults are unscientific.
The most urgent task is to clarify the boundaries between administrative violations and criminal offenses, so that doctors’ legitimate medical decisions are not mistakenly labeled as fraud. Medical insurance policies also need to be updated to align with medical advances, ensuring both doctors can provide effective treatment and patients can receive the care they need. After all, the purpose of policies is to protect people, not to put both doctors and patients in a difficult position.
This incident is not just a simple case of insurance fraud but a reflection of the interplay between medical standards, insurance regulations, and legal boundaries. Resolving it requires cooperation among policymakers, doctors, and patients to find a balance that protects the insurance fund while ensuring patients receive proper treatment. Otherwise, the affected will not only be hemophiliacs but also the entire medical community’s trust in the insurance system.